Free Trial
NASDAQ:TNYA

Tenaya Therapeutics Q2 2025 Earnings Report

Tenaya Therapeutics logo
$0.67 +0.01 (+0.86%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$0.67 +0.00 (+0.01%)
As of 08/8/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tenaya Therapeutics EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Tenaya Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenaya Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Tenaya Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tenaya Therapeutics Earnings Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
Tenaya (TNYA) Q2 Loss Narrows 59%
Q2 EPS Forecast for Tenaya Therapeutics Lowered by Analyst
See More Tenaya Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenaya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenaya Therapeutics and other key companies, straight to your email.

About Tenaya Therapeutics

Tenaya Therapeutics (NASDAQ:TNYA), a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

View Tenaya Therapeutics Profile

More Earnings Resources from MarketBeat